Difficulties in diagnosis and variants of the clinical course of hypertrophic cardiomyopathy in elderly patients

Cover Page

Cite item

Full Text

Abstract

Hypertrophic cardiomyopathy (HCM) is a genetically determined disease with a morphological abnormality of myocardial contractile proteins, manifested by asymmetric left ventricular myocardial hypertrophy. Currently, there is evidence that the HCM incidence rate in the population can be up to 1:200, as opposed to the traditionally quoted 1:500. In early works on HCM, this disease has been mostly perceived as a pathology of young and middle age with a high risk of sudden cardiac death. Now it is generally accepted that patients with HCM are likely to reach the old or even geriatric age subject to the benign course of the disease. Comorbidity in such patients contributes to the clinical aspect of the disease. The article deals with problem areas of HCM diagnostics in elderly patients with an emphasis on differential diagnosis of HCM and left ventricular hypertrophy as part of hypertension. It contains a discussion of differential diagnosis of ischemic heart disease in HCM. The authors also focus on the specifics of the course of HCM in old age patients and present factors affecting the prognosis for this group of patients.

About the authors

Natalia S. Krylova

Pirogov Russian National Research Medical University; City Clinical Hospital №52

Email: krylova_n@list.ru
канд. мед. наук, доц. каф. общей терапии Москва, Россия

Maria Yu. Maslova

Pirogov Russian National Research Medical University

ассистент каф. общей терапии Москва, Россия

Natalia G. Poteshkina

Pirogov Russian National Research Medical University; City Clinical Hospital №52

д-р мед. наук, проф., зав. каф. общей терапии Москва, Россия

Elena A. Kovalevskaya

City Clinical Hospital №52

канд. мед. наук, зав. кардиологическим отд-нием Москва, Россия

Galina B. Selivanova

Pirogov Russian National Research Medical University

д-р мед. наук, проф. каф. общей терапии Москва, Россия

References

  1. Elliott PM, Anastasakis A, Borger MA et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35 (39): 2733-79. doi: 10.1093/eurheartj/ehu284
  2. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/Ameri-can Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 2011; 142: e153-e203.
  3. Semsarian C, Ingles J, Maron MS, Maron BJ. New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2015; 65 (12): 1249-54. doi: 10.1016/j.jacc.2015.01.019
  4. Maron BJ, Bonow RO, Cannon RO et al. Hypertrophic Cardiomyopathy. New Engl J Med 1987; 316 (14): 844-52. doi: 10.1056/nejm198704023161405
  5. Olivotto I, Maron MS, Adabag AS. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46 (3): 480-7.
  6. Canepa M, Pozios I, Vianello PF et al. Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly. Heart 2016; 102 (14): 1087-94. doi: 10.1136/heartjnl-2015-308764
  7. Hata Y, Ichimata S, Yamaguchi Y et al. Clinicopathological and Genetic Profiles of Cases with Myocytes Disarray - Investigation for Establishing the Autopsy Diagnostic Criteria for Hypertrophic Cardiomyopathy. J Clin Med 2019; 8 (4): 463. doi: 10.3390/jcm8040463
  8. Mademont-Soler I, Mates J, Yotti R et al. Additional value of screening for minor genes and copy number variants in hypertrophic cardiomyopathy. PLoS One 2017; 12 (8): e0181465.
  9. Kubo T, Kitaoka H, Okawa M et al. Hypertrophic cardiomyopathy in the elderly. Geriatr Gerontol Int 2010; 10 (1): 9-16.
  10. Niimura, H. Sarcomere Protein Gene Mutations in Hypertrophic Cardiomyopathy of the Elderly. Circulation 2002; 105 (4): 446-51. doi: 10.1161/hc0402.102990
  11. Razmara E, Garshasbi M. Whole-exome sequencing identifies R1279X of MYH6 gene to be associated with congenital heart disease. BMC Cardiovasc Dis 2018; 18 (1): 137. doi: 10.1186/s12872-018-0867-4
  12. Rowin EJ, Maron MS, Wells S et al. Impact of Sex on Clinical Course and Survival in the Contemporary Treatment Era for Hypertrophic Cardiomyopathy. J Am Heart Assoc 2019; 8 (21): e012041. doi: 10.1161/JAHA.119.012041
  13. Gupta T, Harikrishnan P, Kolte D et al. Outcomes of Acute Myocardial Infarction in Patients with Hypertrophic Cardiomyopathy. Am J Med 2015; 128 (8), 879-87.e1. doi: 10.1016/j.amjmed.2015.02.025
  14. Полякова А.А., Баранова Е.И., Семернин Е.Н. и др. Гендерные различия клинического течения и ремоделирования сердца при идиопатической гипертрофической кардиомиопатии в пожилом возрасте. Рос. кардиологический журн. 2018; 2: 13-8. doi: 10.15829/1560-4071-2018-2-13-18
  15. Van Velzen HG, Schinkel AFL, Baart SJ et al. Effect of Gender and Genetic Mutations on Outcomes in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2018; 122 (11): 1947-54. doi: 10.1016/j.amjcard.2018.08.040
  16. Kato TS. Discrimination of Nonobstructive Hypertrophic Cardiomyopathy From Hypertensive Left Ventricular Hypertrophy on the Basis of Strain Rate Imaging by Tissue Doppler Ultrasonography. Circulation 2004; 110 (25): 3808-14. doi: 10.1161/01.cir.0000150334.69355.00
  17. Karam R, Lever HM, Healy BP. Hypertensive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with hypertension? A study of 78 patients. J Am Coll Cardiol 1989; 13 (3): 580-4. doi: 10.1016/0735-1097 (89)90596-2
  18. Aslam F, Haque A, Foody J, Shirani J. The Frequency and Functional Impact of Overlapping Hypertension on Hypertrophic Cardiomyopathy: A Single-Center Experience. J Clin Hypertens 2010; 12 (4): 240-5. doi: 10.1111/j.1751-7176.2009.00251.x2010
  19. Takeda A, Takeda N. Different pathophysiolody of cardiac hyperthrophy in hypertension and hypertrophic cardiomyopathy. J Mol Cell Cardiol 1997; 29 (11): 2961-5.
  20. Ковалевская Е.А., Крылова Н.С., Потешкина Н.Г. и др. Гипертрофическая кардиомиопатия в сочетании с ишемической болезнью сердца: 6-летняя история наблюдения. Рос. кардиологический журн. 2018; 9: 48-53. doi: 10.15829/1560-4071-2018-9-48-53
  21. Shin DG, Son J-W, Park JY et al. Impact of coronary artery anatomy on clinical course and prognosis in apical hypertrophic cardiomyopathy: analysis of coronary angiography and computed tomography. Korean Circ J 2015; 45 (1): 38-43. doi: 10.4070/kcj.2015.45.1.38
  22. Sorajja P, Ommen SR, Nishimura RA et al. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation 2003; 108 (19): 2342-8. doi: 10.1161/01.CIR.0000097110.55312.BF
  23. Sado DM, Iqbal J. Hypertrophic cardiomyopathy in older patients. Clin Med (Lond) 2010; 10 (2): 196-8. doi: 10.7861/clinmedicine.10-2-196
  24. Каплунова В.Ю., Шакарьянц Г.А., Кожевникова М.В. и др. Гипертрофическая кардиомиопатия: формы и варианты течения, подходы к фармакотерапии. Клин. мед. 2017; 95 (12): 1061-9. doi: 10.18821/0023-2149-2017-95-12-1061-1069
  25. Полякова А.А., Гудкова А.Я., Крутиков А.Н. и др. Гипертрофическая кардиомиопатия в старшей возрастной группе: влияние факторов кардиометаболического риска и полиморфизма гена MADD. Артериальная гипертензия. 2018; 24 (1): 29-40. doi: 10.18705/1607-419X-2018-24-1-29-40
  26. Maron BJ, Rowin EJ, Casey SA et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >60 years of age. Circulation 2013; 127 (5): 585-93.
  27. Maron BJ, Casey SA, Haas TS et al. Hypertrophic Cardiomyopathy With Longevity to 90 Years or Older. Am J Cardiol 2012; 109 (9): 1341-7. doi: 10.1016/j.amjcard.2011.12.027
  28. Tsuda T, Hayashi K, Fujino N et al. Impact of Hypertrophic Cardiomyopathy on Prediction of Thromboembolism in Patients with Non-valvular Atrial Fibrillation. Heart Rhythm 2018. doi: 10.1016/j.hrthm.2018.11.029
  29. Haruki S, Minami Y, Hagiwara N. Stroke and Embolic Events in Hypertrophic Cardiomyopathy. Stroke 2016; 47 (4): 936-42. doi: 10.1161/strokeaha.115.012130
  30. Kubo T, Kitaoka H, Okawa M et al. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy: results from Kochi RYOMA Study. Circ J 2009; 73: 1599-605.
  31. Siontis KC, Geske JB, Ong K et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc 2014; 3 (3): e001002. doi: 10.1161/JAHA.114.001002
  32. Javidgonbadi D, Andersson B, Abdon NJ et al. Factors influencing long-term heart failure mortality in patients with obstructive hypertrophic cardiomyopathy in Western Sweden: probable dose-related protection from beta-blocker therapy. Open Heart 2019; 6 (1): e000963. doi: 10.1136/openhrt-2018-000963

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies